Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

NCT02582242 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

437

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Type 2 Diabetes Mellitus

Interventions

DRUG: biphasic insulin aspart 30

Sponsor

Novo Nordisk A/S